Monoclonal antibody-based therapy for renal cell carcinoma.
SourceUrologic Clinics of North America, 30, 3, (2003), pp. 623-31
Article / Letter to editor
Display more detailsDisplay less details
Urologic Clinics of North America
SubjectUMCN 1.4: Immunotherapy, gene therapy and transplantation
Monoclonal antibody G250 treatment may have a role in the management of metastatic RCC; however, particular subgroups who are more prone to benefit from this treatment must be delineated. High-risk patients may benefit from adjuvant treatment with this nontoxic treatment modality. Large cohort studies are needed to investigate this possibility.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.